Literature DB >> 2440376

From fenfluramine racemate to d-fenfluramine. Specificity and potency of the effects on the serotoninergic system and food intake.

S Garattini, T Mennini, R Samanin.   

Abstract

Experiments using the binding of various ligands for monoamines to rat brain membranes and synaptosomal preparations for studying monoamine uptake and release have shown that d-fenfluramine is more potent than the l isomer in inhibiting 5-HT uptake, whereas d-norfenfluramine preferentially releases 5-HT from a reserpine-insensitive compartment. Studies on brain monoamine metabolism in intact animals have shown that the d and l isomers of fenfluramine at relatively low doses have a specific action on brain 5-HT and catecholamines, respectively. Based on the different ability of metergoline and ritanserin to displace 5-HT2 binding to rat brain membranes and to antagonize d-fenfluramine's anorexia, evidence has been provided that d-fenfluramine preferentially uses 5-HT1 sites in the rat brain to cause anorexia in this animal species. Finally, characteristics, regional distribution, and pharmacological characterization of a high-affinity [3H]d-fenfluramine binding to rat brain membranes have been described. This binding appears to be different from 5-HT uptake sites ([3H]imipramine binding) and 5-HT receptors and is not regionally related to the endogenous levels of 5-HT in the rat brain. It is, however, preferentially displaced by some agents using 5-HT to cause anorexia in rats, raising the possibility that it is somewhat related to 5-HT mechanisms involved in feeding control.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2440376     DOI: 10.1111/j.1749-6632.1987.tb36207.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  19 in total

Review 1.  Reactive astrogliosis after spinal cord injury-beneficial and detrimental effects.

Authors:  Soheila Karimi-Abdolrezaee; Rohini Billakanti
Journal:  Mol Neurobiol       Date:  2012-06-09       Impact factor: 5.590

2.  Evidence for 5-HT2 receptor mediation in quipazine anorexia.

Authors:  R Shukla; D MacKenzie-Taylor; R H Rech
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

3.  Quipazine reduces food intake in the rat by activation of 5-HT2-receptors.

Authors:  G Hewson; G E Leighton; R G Hill; J Hughes
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

Review 4.  Dexfenfluramine. Its place in weight control.

Authors:  P Turner
Journal:  Drugs       Date:  1990       Impact factor: 9.546

5.  A comparison of the effects of d- and l-fenfluramine and d-amphetamine on energy and macronutrient intake in human subjects.

Authors:  E Goodall; S Feeney; J McGuirk; T Silverstone
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

6.  The emerging modern face of mood disorders: a didactic editorial with a detailed presentation of data and definitions.

Authors:  Konstantinos N Fountoulakis
Journal:  Ann Gen Psychiatry       Date:  2010-04-12       Impact factor: 3.455

7.  5-HT2a/2c receptor blockade by amesergide fully attenuates prolactin response to d-fenfluramine challenge in physically healthy human subjects.

Authors:  E F Coccaro; R J Kavoussi; M Oakes; T B Cooper; R Hauger
Journal:  Psychopharmacology (Berl)       Date:  1996-07       Impact factor: 4.530

8.  Comparative studies on the anorectic activity of d-fenfluramine in mice, rats, and guinea pigs.

Authors:  T Mennini; A Bizzi; S Caccia; A Codegoni; C Fracasso; E Frittoli; G Guiso; I M Padura; C Taddei; A Uslenghi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

9.  Effect of dexfenfluramine on sleep in healthy subjects.

Authors:  M Wiegand; S Bossert; R Kinney; K M Pirke; J C Krieg
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

10.  Reciprocal interaction of 5-hydroxytryptamine and cholecystokinin in the control of feeding patterns in rats.

Authors:  G Grignaschi; B Mantelli; C Fracasso; M Anelli; S Caccia; R Samanin
Journal:  Br J Pharmacol       Date:  1993-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.